Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Short Communication Volume 6 Issue 7

Tackle an Oncogene without Forgetting to Activate a Tumor Suppressor One

Daniel Gandia1* and Paulus S Wang2,3,4

1Universidad de Buenos Aires–Consejo Nacional de Investigaciones Científicas y Técnicas, Facultad de Ciencias Exactas y Naturales, Instituto de Física del Plasma, Buenos Aires, Argentina
2Medical Center of Aging Research, China Medical University Hospital, Taiwan, ROC
3Department of Biotechnology, College of Health Science, Asia University, Taiwan, ROC
4Department of Physiology, National Yang Ming Chiao Tung University, Taiwan, ROC

*Corresponding Author: Daniel Gandia, Universidad de Buenos Aires–Consejo Nacional de Investigaciones Científicas y Técnicas, Facultad de Ciencias Exactas y Naturales, Instituto de Física del Plasma, Buenos Aires, Argentina.

Received: November 04, 2022; Published: November 22, 2022

Opinion

Cancer cells have many ways to evade homeostatic body mechanisms.

Some of these are essentials for the “milieu interior” of Claude Bernard, for rheologic pathways are severely altered in tumors: coagulation serving for, and platelets helping in the metastatic cascade, and disseminated intravascular coagulation as a paraneoplastic phenomenon. So here we have examples of the opposite “rule” of Claude Bernard: there is no homeostasis of the hemostasis.

Keywords: Cancer; P53; KRAS; Oncogenes; Tumor Suppressor Genes; Tumor Evolution

References

  1. Punekar SR., et al. “The current state of the art and future trends in RAS-targeted cancer therapies”. Nature Reviews Clinical Oncology 19 (2022): 637-655.
  2. Einsenstein M. “Restoring the guardian of the genome”. Nature Outline 603 (2022).
  3. Hassin O., et al. “Drugging p53 in cancer: one protein, many targets”. Nature Reviews Drug Discovery; October 10, (2022).
  4. Longo D., et al. “Targeting Oncogenic RAS protein”. The New England Journal of Medicine 387 (2022): 184-186.

Citation

Citation: Daniel Gandia and Paulus S Wang. “Tackle an Oncogene without Forgetting to Activate a Tumor Suppressor One" Acta Scientific Cancer Biology 6.7 (2022): 04-05.

Copyright

Copyright: © 2022 Daniel Gandia and Paulus S Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor1.183

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US